Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: Twenty cancer centres, six agents, one database

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3314-3320

  Poprach, Alexandr ^a   Bortlíček, Zbyněk ^b   Büchler, Tomáš ^c   Melichar, Bohuslav ^d   Lakomý, Radek ^a   Vyzula, Rostislav ^a   Brabec, Petr ^b   Svoboda, Marek ^a   Dušek, Ladislav ^b   Gregor, Jakub ^b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cancer care; Clinical registry; Database; Population based data; Renal cell carcinoma; Targeted therapy

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CLINICAL PRACTICE; CONTROLLED STUDY; CZECH REPUBLIC; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLIC HEALTH INSURANCE; REVIEW; ARTICLE; FACTUAL DATABASE; KIDNEY TUMOR; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; REGISTER;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CZECH REPUBLIC; DATABASES, FACTUAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; REGISTRIES;

EID: 84877097130     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0286-9     Document Type: Review

References (22)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 (online). International Agency for Research on Cancer, Lyon, France, 2010. Available from: http://globocan.iarc.fr.
2. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiology of malignant tumours in the Czech Republic (online). Masaryk University, Czech Republic. 2005. Available from: http://www.svod.cz. Version 7.0 [2007], ISSN 1802-8861.
3. Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer incidence and mortality in the Czech Republic (in Czech). Klin Onkol. 2010;23(5):311-24.
4. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556-63.
5. Jäger D, Ma J, Korbenfeld E, Zemanová M, Leonhartsberger N, Stauch K, et al. PREDICT (Patient Characteristics in REnal Cell Carcinoma and Daily PractICe Treatment With Sorafenib) non-interventional study - final report. Eur J Cancer. 2011;47(1):S520.
6. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26(22):3743-8.
7. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010;58(6):906-11.
8. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116(23):5383-90.
9. Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer. 2011;105(11):1635-9.
10. Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34(6):310-4.
11. Bergmann L, Kube U, Kindler M, Koepke T, Steiner G, Janssen J, et al. A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: results of a preplanned interim analysis of a prospective study. American Society of Clinical Oncology (ASCO) annual meeting; 3-7 June 2011; Chicago, Illinois, USA.
12. Büchler T, Klapka R, Melichar B, Brabec P, Dušek L, Vyzula R, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol. 2012;23(2):395-401.
13. Nadkarni PM, Brandt C, Frawley S, Sayward FG, Einbinder R, Zelterman D, et al. Managing attribute - value clinical trials data using the ACT/DB client-server database system. J Am Med Inf Assoc. 1998;5(2):139-51.
14. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11.
15. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-65.
16. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24.
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
19. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
20. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2):430-4.
21. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. Nov 5 2011 [Epub ahead of print].
22. Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011;60(6):1163-70.